(Total Views: 314)
Posted On: 04/24/2018 6:25:57 PM
Post# of 72436
![Avatar](https://investorshangout.com/images/ProfileImages/398685088_3064_306524.png)
Article - Early phase clinical trial shows promise for advanced head and neck cancer
Nine out of 10 patients treated with the experimental therapy saw their tumors shrink
https://www.fredhutch.org/en/news/center-news...ancer.html
Nine out of 10 patients treated with the experimental therapy saw their tumors shrink
Quote:
When Méndez and Kemp applied the functional genomics technique to head and neck cancer cells with mutations in a gene known as p53, which is mutated in approximately two-thirds of head and neck cancers, their screen identified a gene known as Wee1 as a potential Achilles heel for these tumor cells. Luckily for the researchers, there was already a drug — AZD1775 — that targets Wee1.
When Méndez and Chow designed the clinical trial, they allowed patients with or without mutations in p53 to join — additional preclinical data from Méndez’s team had found that the drug also seemed to work on cancerous cells without a p53 mutation but where the cancer was triggered by HPV infection, a cancer-linked virus that inactivates p53 in a different way.
Indeed, three of the trial participants who had a good response to the drug did not carry p53 mutations in their tumors but were HPV-positive.
https://www.fredhutch.org/en/news/center-news...ancer.html
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)